Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1386301/000155837022001132/rsss-20211231x10q.htm
May 2022
March 2022
February 2022
February 2022
November 2021
November 2021
October 2021
September 2021
April 2021
March 2021
Exhibit 99.1
Research Solutions Reports Fiscal Second Quarter 2022 Results
Reports Record 56 Net New Platform Deployments and 36 Percent Increase in ARR to $6.8 Million
HENDERSON, Nev., February 10, 2022 — Research Solutions, Inc. (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, reported financial results for its fiscal second quarter ended December 31, 2021.
Fiscal Second Quarter 2022 Summary
· | Total revenue of $7.9 million, a 5.7% increase from prior-year quarter |
· | Platform revenue up 31% to $1.6 million. Annual Recurring Revenue (“ARR”) up 36% to $6.8 million |
· | Gross profit up 19% from prior-year quarter. Total gross margin improved 390 basis points to 36.0% |
· | Loss of $0.02 per share, compared to a loss of $0.01 per share in the prior-year quarter |
· | Platform incremental ARR generated in the quarter was a record high of $0.6M. The Company has now generated $1.8M of incremental platform ARR in the past twelve months. |
· | 56 net new platform deployments in the quarter compared to 29 in the prior-year |
“In the second quarter we saw a record number of new customers adopt the platform, and existing customers continue to increase the number of features they subscribe to as they expand the licensed number of users,” said Roy W. Olivier, President and CEO of Research Solutions. “The increase in ARR during the quarter reflects continued operational efficiencies, more accountability from our sales teams, and a deeper focus on innovative new product upgrades. We believe we are well-positioned for growth in the second half of fiscal 2022.”
Fiscal Second Quarter 2022 Results
Total revenue was $7.9 million, a 5.7% increase from $7.4 million in the year-ago quarter as both platform and transaction revenue increased from the prior period.
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1386301/000155837022001132/rsss-20211231x10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Research Solutions, Inc..
Research Solutions, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
Adjusted EBITDA has limitations as an analytical tool, which includes, among others, the following: Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; Adjusted EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; and Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.
General and administrative 497,385 Increased due to greater personnel costs and consulting and legal expenses.
General and administrative 833,546 Increased due to greater personnel costs and consulting and legal expenses.
Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
Set forth below is a reconciliation of Adjusted EBITDA to net income (loss) for the three and six months ended December 31, 2021 and 2020: 29 We present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.
Transactions 1.1 Decreased primarily due...Read more
Transactions 0.3 Decreased primarily due...Read more
We apply the following five...Read more
Technology and product development 441,988...Read more
In addition, we use Adjusted...Read more
To date, we have not...Read more
Furthermore, capital markets and economies...Read more
20 Revenues are recognized when...Read more
We leverage our Platform's efficiencies...Read more
27 Net loss increased $607,626...Read more
The severity of the impact...Read more
In evaluating Adjusted EBITDA, you...Read more
Greater personnel costs include separation...Read more
Greater personnel costs include separation...Read more
Transactions 38,258 Increased primarily due...Read more
However, Adjusted EBITDA is not...Read more
Platforms 3.4 Decreased primarily due...Read more
Platforms 2.5 Decreased primarily due...Read more
In addition to our GAAP...Read more
Transactions 335,849 Decreased primarily due...Read more
Net Income (Loss) Net loss...Read more
Our presentation of Adjusted EBITDA...Read more
24 Total revenue increased $416,631,...Read more
There were no outstanding borrowings...Read more
Stock-Based Compensation The fair value...Read more
We define Adjusted EBITDA as...Read more
The following table sets forth...Read more
Cost of Revenue The difference...Read more
We derive our revenues from...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Research Solutions, Inc. provided additional information to their SEC Filing as exhibits
Ticker: RSSS
CIK: 1386301
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-22-001132
Submitted to the SEC: Mon Feb 14 2022 5:20:22 PM EST
Accepted by the SEC: Mon Feb 14 2022
Period: Friday, December 31, 2021
Industry: Business Services